TONG REN TANG TECHNOLOGIES CO. LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.45 HKD | +1.87% |
|
+2.64% | -16.79% |
| Sales 2024 * | 7.5B 1.04B 8.09B | Sales 2025 * | 8.25B 1.14B 8.9B | Capitalization | 6.47B 893M 6.98B |
|---|---|---|---|---|---|
| Net income 2024 * | 631M 87.15M 681M | Net income 2025 * | 674M 93.09M 727M | EV / Sales 2024 * | 0.8 x |
| Net cash position 2024 * | 499M 68.97M 539M | Net cash position 2025 * | 2.32B 321M 2.51B | EV / Sales 2025 * | 0.5 x |
| P/E ratio 2024 * |
10.2
x | P/E ratio 2025 * |
9.53
x | Employees | 4,101 |
| Yield 2024 * |
3.37% | Yield 2025 * |
3.96% | Free-Float | 45.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.87% | ||
| 1 week | +2.64% | ||
| Current month | +0.74% | ||
| 1 month | +6.86% | ||
| 3 months | +1.11% | ||
| 6 months | -9.47% | ||
| Current year | -16.79% |
1 week
5.23
5.50
1 month
4.665.50
Current year
4.666.66
1 year
4.668.97
3 years
3.809.28
5 years
3.8010.88
10 years
3.8016.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Fu Chen
CEO | Chief Executive Officer | 55 | 23-06-14 |
Guan Zhao Han
LAW | General Counsel | 45 | - |
Shu Wu Zhao
PRN | Corporate Officer/Principal | 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leung Huel Ting
BRD | Director/Board Member | 70 | 00-10-10 |
Ching Har Chan
BRD | Director/Board Member | 67 | 18-06-11 |
Yuan Jing Zhan
BRD | Director/Board Member | 80 | 18-06-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +2.11% | - | |
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 5.45 | +1.87% | 1,511,000 |
| 24-05-02 | 5.35 | -1.11% | 1,505,000 |
| 24-04-30 | 5.41 | +1.50% | 2,641,000 |
| 24-04-29 | 5.33 | +0.38% | 1,874,000 |
| 24-04-26 | 5.31 | +7.71% | 3,074,000 |
Delayed Quote Hong Kong S.E., May 03, 2024 at 04:09 am EDT
More quotes
Tong Ren Tang Technologies Co Ltd is a China-based company mainly engaged in the manufacture and sale of traditional Chinese medicine products. The Company's main businesses includes the production, retail and wholesale of traditional Chinese medicine products and health care products and the provision of traditional Chinese medicine diagnosis and treatment services. The Company is also engaged in the production, processing and acquisition of Chinese herbal medicines, drug sales, medical services and advertising. The Company mainly distributes its products in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.049
CNY
Average target price
6.058
CNY
Spread / Average Target
+19.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.79% | 894M | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.19B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 1666 Stock
